T. Rowe Price Associates
CRBU icon

T. Rowe Price Associates’s Caribou Biosciences CRBU Stock Holding History

T. Rowe Price Associates’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,848
Closed -$33K – 3077
2025
Q1 		$33K Hold
35,848
– – ﹤0.01% 2973
2024
Q4 		$57K Buy
35,848
+8,008
+29% +$16.1K ﹤0.01% 2917
2024
Q3 		$55K Buy
27,840
+3,888
+16% +$7.96K ﹤0.01% 2915
2024
Q2 		$40K Buy
23,952
+572
+2% +$1.83K ﹤0.01% 2876
2024
Q1 		$121K Buy
23,380
+2,545
+12% +$15.7K ﹤0.01% 2745
2023
Q4 		$120K Buy
20,835
+4,637
+29% +$22.9K ﹤0.01% 2686
2023
Q3 		$78K Buy
16,198
+5,652
+54% +$35.1K ﹤0.01% 2707
2023
Q2 		$45K Hold
10,546
– – ﹤0.01% 2813
2023
Q1 		$56K Buy
+10,546
New +$65.7K ﹤0.01% 2775

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's CRBU Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Caribou Biosciences (CRBU) in Q2 2025, closing a stake of 35,848 shares — an estimated $33K sold.

T. Rowe Price Associates first reported a position in CRBU in Q1 2023 and held it in 9 quarters. The position peaked at $121K in Q1 2024. 129 funds tracked by Wall St. Rank hold CRBU as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Caribou Biosciences position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 35,848 Caribou Biosciences shares in Q2 2025, an estimated $33K.
  • T. Rowe Price Associates first reported a position in Caribou Biosciences in Q1 2023 and held it in 9 quarters.
  • T. Rowe Price Associates's Caribou Biosciences position peaked at $121K in Q1 2024.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.